Form 4: CRISPR Therapeutics Executive Granted Stock Options and Restricted Stock Units

James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics, received stock options for 18,333 shares and restricted stock units for 30,000 shares on October 16, 2024.

Summary

• James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics AG, was granted stock options and restricted stock units on October 16, 2024.
• The stock options are for 18,333 common shares with an exercise price of $49.
• These options vest in 48 equal monthly installments starting November 16, 2024.
• Kasinger also received 30,000 restricted stock units, each representing a contingent right to receive one share of CRSP Common Shares.
• These restricted stock units vest on October 16, 2027.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it incentivizes management. The sentiment is therefore moderately positive.

Positives

• The grant of stock options and restricted stock units aligns the executive's interests with those of the shareholders.
• The vesting schedules incentivize long-term performance and retention.

Industry Context

Stock option and RSU grants are standard practice in the biotech industry to attract and retain key personnel, aligning their interests with company performance and shareholder value.

Comparison to Industry Standards

• Executive compensation packages in the biotechnology industry typically include a mix of salary, stock options, and restricted stock units.
• Companies like Vertex Pharmaceuticals and BioMarin Pharmaceutical also utilize similar equity-based compensation to incentivize their executives.
• The vesting schedules are also typical, with options vesting over several years to encourage long-term commitment.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align management's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates